SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

INDEX SEARCH RESULT

2019.09.13 | 14:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis - HTML (w)

2019.09.13 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis - HTML (w)

2019.09.13 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer - HTML (w)

2019.09.12 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum - HTML (w)

2019.09.12 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy - HTML (w)

2019.09.10 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS - HTML (w)

2019.09.09 | 07:00 | Permanent Information Releases / General Company News

German version HTML (w) Mail

SIKA

puce SIKA ÜBERNIMMT HERSTELLER VON SILIKON-DICHT- UND KLEBSTOFFEN IN CHINA - HTML (w)

2019.09.09 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SIKA

puce SIKA ACQUIRES MANUFACTURER OF SILICONE SEALANTS AND ADHESIVES IN CHINA - HTML (w)

2019.09.06 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer - HTML (w)

2019.09.06 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer - HTML (w)

2019.09.04 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS - HTML (w)

2019.09.03 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine - HTML (w)

2019.09.03 | 07:00 | Permanent Information Releases / General Company News

German version HTML (w) Mail

SIKA

puce SIKA NIMMT IN KAMERUN NEUE MÖRTELFABRIK IN BETRIEB - HTML (w)

2019.09.03 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SIKA

puce SIKA COMMISSIONS NEW MORTAR FACTORY IN CAMEROON - HTML (w)

2019.09.03 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000